Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II

Young Joon Hong, Myung Ho Jeong, Jang Ho Bae, Seok Kyu Oh, Seung-Woon Rha, Seung Ho Hur, Sung Yun Lee, Sang Wook Kim, Kwang Soo Cha, In Ho Chae, Tae Hoon Ahn, Kee Sik Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aims: We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients. Methods: Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy endpoint was composite of cardiac death, nonfatal myocardial infarction, target-le-sion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month. Results: There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (–42.05 ± 32.73 mg/dL vs. –34.23 ± 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (–20.16 ± 54.49 mg/dL in 4 mg group and –24.45 ± 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (–0.13% ± 1.21% in 4 mg group and –0.04% ± 1.10% in 2 mg group, p = 0.256 and p = 0.671, respectively). Conclusions: Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.

Original languageEnglish
Pages (from-to)656-667
Number of pages12
JournalKorean Journal of Internal Medicine
Volume32
Issue number4
DOIs
Publication statusPublished - 2017 Jul 1

    Fingerprint

Keywords

  • Atherosclerosis
  • Hydroxymethylglu-taryl-CoA reductase inhibitors
  • Lipids
  • Myocardial infarction

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Hong, Y. J., Jeong, M. H., Bae, J. H., Oh, S. K., Rha, S-W., Hur, S. H., Lee, S. Y., Kim, S. W., Cha, K. S., Chae, I. H., Ahn, T. H., & Kim, K. S. (2017). Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II. Korean Journal of Internal Medicine, 32(4), 656-667. https://doi.org/10.3904/kjim.2016.016